$IDXX

IDEXX LABORATORIES INC /DE

IDEXX develops, manufactures and distributes products and services primarily for companion animal veterinary, livestock, poultry and dairy, and water testing markets. Its three primary segments are Companion Animal Group, Water quality products, and Livestock, Poultry and Dairy; its Other segment includes human medical point-of-care diagnostic products and an out-licensing arrangement. The Companion Animal Group sells veterinary diagnostic instruments, consumables and rapid tests, reference laboratory and consulting services, practice management software, and diagnostic imaging systems. Water products test for microbiological contaminants, while livestock, poultry and dairy offerings include diagnostic tests, herd health services and milk testing products. IDEXX also sells point-of-care analyzers and consumables for human medical hospitals and clinics. It earns money from product sales and diagnostic, consulting, software and related services. IDEXX markets worldwide through direct sales groups, distributors and resellers. Its headquarters are in Westbrook, Maine.

1
1
0
—
$27.4M
MAZELSKY JONATHAN JAY
0%
See all $IDXX insider activity →
Low

Invesco S&P 500 Equal Weight (RSP) Buys $0.7 Million More PTC on Nov. 16

Invesco S&P 500 Equal Weight ETF (RSP) bought $0.7 million worth of PTC Inc shares on Nov. 16, adding 3,427 shares to its position. The fund also increased stakes in IDXX, MRNA, and other companies. RSP has $104.44 billion in assets and a 0.2% expense ratio, with a year-to-date return of 13.98%.

Rising vet bills drive more Americans to pet insurance

Rising veterinary costs are driving more Americans to purchase pet insurance, with 7 million pets insured in 2025, up 9% from the previous year. Pet insurance can help cover expensive treatments, but may not be cost-effective for all owners. Premiums are projected to rise 17% to $6.4 billion in 2026. Zoetis and IDEXX Laboratories are mentioned for their contributions to advanced pet treatments and diagnostics.

How IDEXX Stock Is Engineered To Make Money For You

IDEXX Laboratories (IDXX) stock rose 32.4% since October 7, driven by Q3 results and an improved outlook. The company reduced its share count from 84.0M to 79.0M through buybacks, boosting EPS growth. IDXX trades at 44.7x earnings, funded by its profitable pet diagnostics business. Management expects strong free cash flow and raised 2026 revenue and EPS guidance.

IDXX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning IDXX (IDEXX LABORATORIES INC /DE). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent IDXX coverage spans insider activity, financial news and sector analysis.

In the last 30 days, IDXX insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($27.4M). The most active reporter was MAZELSKY JONATHAN JAY, Executive Chair of the Board, with 13 filings.

What's driving IDXX

AlphAI scores every news story that mentions IDXX with an AI model for sentiment and relevance, and aggregates insider trades from IDEXX LABORATORIES INC /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IDXX

Score

Rising vet bills drive more Americans to pet insurance

Rising veterinary costs are driving more Americans to purchase pet insurance, with 7 million pets insured in 2025, up 9% from the previous year. Pet insurance can help cover expensive treatments, but may not be cost-effective for all owners. Premiums are projected to rise 17% to $6.4 billion in 2026. Zoetis and IDEXX Laboratories are mentioned for their contributions to advanced pet treatments and diagnostics.

How IDEXX Stock Is Engineered To Make Money For You

IDEXX Laboratories (IDXX) stock rose 32.4% since October 7, driven by Q3 results and an improved outlook. The company reduced its share count from 84.0M to 79.0M through buybacks, boosting EPS growth. IDXX trades at 44.7x earnings, funded by its profitable pet diagnostics business. Management expects strong free cash flow and raised 2026 revenue and EPS guidance.

Rising vet bills drive more Americans to pet insurance

Rising veterinary costs, driven by advanced treatments, are increasing pet insurance adoption in the US. About 7 million pets were insured in 2025, up 9% from the previous year. Premiums are projected to reach $6.4 billion in 2026, with average annual veterinary spending at $560. Companies like Embrace Pet Insurance and Trupanion report growing claims and subscriptions. Zoetis and IDEXX Laboratories are among those providing advanced treatments and diagnostics.

Related tickers